GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovoRx Inc (NAS:RNXT) » Definitions » EPS without NRI

RNXT (RenovoRx) EPS without NRI : $-0.78 (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is RenovoRx EPS without NRI?

RenovoRx's earnings per share without non-recurring items for the three months ended in Jun. 2024 was $-0.12. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.78.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -36.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for RenovoRx's EPS without NRI or its related term are showing as below:

RNXT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -36.7   Med: -35.15   Max: -33.6
Current: -36.7

During the past 5 years, RenovoRx's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -33.60% per year. The lowest was -36.70% per year. And the median was -35.15% per year.

RNXT's 3-Year EPS without NRI Growth Rate is ranked worse than
85.57% of 1268 companies
in the Biotechnology industry
Industry Median: 4.9 vs RNXT: -36.70

RenovoRx's EPS (Diluted) for the three months ended in Jun. 2024 was $-0.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.60.

RenovoRx's EPS (Basic) for the three months ended in Jun. 2024 was $-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.60.


RenovoRx EPS without NRI Historical Data

The historical data trend for RenovoRx's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovoRx EPS without NRI Chart

RenovoRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
-0.46 -0.45 -1.22 -1.09 -1.16

RenovoRx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.27 -0.22 -0.16 -0.12

Competitive Comparison of RenovoRx's EPS without NRI

For the Biotechnology subindustry, RenovoRx's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovoRx's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where RenovoRx's PE Ratio without NRI falls into.



RenovoRx EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RenovoRx  (NAS:RNXT) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


RenovoRx EPS without NRI Related Terms

Thank you for viewing the detailed overview of RenovoRx's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


RenovoRx Business Description

Traded in Other Exchanges
N/A
Address
4546 El Camino Real, Suite B1, Los Altos, CA, USA, 94022
RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 pancreatic cancer clinical trial for its lead product candidate RenovoGem.
Executives
Angela Nelms officer: Chief Operating Officer C/O RENOVORX, INC., 4546 EL CAMINO REAL, SUITE B1, LOS ALTOS CA 94022
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
James M Ahlers officer: Chief Financial Officer 2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Ramtin Agah director, officer: Chief Medical Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Shaun Bagai director, officer: Chief Executive Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Bank Of The West 10 percent owner PO BOX 60078, LOS ANGELES CA 90060
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
David Diamond director 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Laurence Marton director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kirsten Angela Macfarlane director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Christopher John Lehman officer: Chief Financial Officer 65 OAK RIDGE ROAD, BERKELEY, BERKELEY CA 94705
Paul Manners officer: Chief Financial Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kamran Najmabadi 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303
Najmabadi Family Trust Dated April 22, 2021 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303

RenovoRx Headlines

From GuruFocus

RenovoRx Reports Third Quarter 2022 Financial Results

By Business Wire Business Wire 11-14-2022